nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—ADRA1D—polycystic ovary syndrome	0.306	0.412	CbGaD
Doxepin—ADRA1B—polycystic ovary syndrome	0.261	0.351	CbGaD
Doxepin—ADRA1A—polycystic ovary syndrome	0.176	0.237	CbGaD
Doxepin—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.00498	0.0962	CcSEcCtD
Doxepin—Sinus congestion—Metformin—polycystic ovary syndrome	0.00261	0.0505	CcSEcCtD
Doxepin—CYP2C19—urine—polycystic ovary syndrome	0.00199	0.0557	CbGeAlD
Doxepin—Fungal infection—Metformin—polycystic ovary syndrome	0.00168	0.0325	CcSEcCtD
Doxepin—CYP1A2—urine—polycystic ovary syndrome	0.00163	0.0455	CbGeAlD
Doxepin—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00161	0.031	CcSEcCtD
Doxepin—CYP2C9—urine—polycystic ovary syndrome	0.00154	0.0432	CbGeAlD
Doxepin—HTR2A—urine—polycystic ovary syndrome	0.00127	0.0356	CbGeAlD
Doxepin—CYP3A4—urine—polycystic ovary syndrome	0.00118	0.0329	CbGeAlD
Doxepin—CYP2D6—urine—polycystic ovary syndrome	0.00116	0.0324	CbGeAlD
Doxepin—Ear pain—Metformin—polycystic ovary syndrome	0.00111	0.0214	CcSEcCtD
Doxepin—Nasal congestion—Metformin—polycystic ovary syndrome	0.00104	0.02	CcSEcCtD
Doxepin—Lethargy—Metformin—polycystic ovary syndrome	0.000964	0.0186	CcSEcCtD
Doxepin—Pain in extremity—Metformin—polycystic ovary syndrome	0.000944	0.0182	CcSEcCtD
Doxepin—Migraine—Metformin—polycystic ovary syndrome	0.000929	0.0179	CcSEcCtD
Doxepin—Breast disorder—Metformin—polycystic ovary syndrome	0.000853	0.0165	CcSEcCtD
Doxepin—Cramp muscle—Metformin—polycystic ovary syndrome	0.00085	0.0164	CcSEcCtD
Doxepin—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000844	0.0163	CcSEcCtD
Doxepin—Influenza—Metformin—polycystic ovary syndrome	0.000816	0.0157	CcSEcCtD
Doxepin—HRH2—adrenal gland—polycystic ovary syndrome	0.000768	0.0215	CbGeAlD
Doxepin—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000759	0.0146	CcSEcCtD
Doxepin—Infestation NOS—Metformin—polycystic ovary syndrome	0.000728	0.014	CcSEcCtD
Doxepin—Infestation—Metformin—polycystic ovary syndrome	0.000728	0.014	CcSEcCtD
Doxepin—Drowsiness—Metformin—polycystic ovary syndrome	0.000728	0.014	CcSEcCtD
Doxepin—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000713	0.0138	CcSEcCtD
Doxepin—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000688	0.0133	CcSEcCtD
Doxepin—ORM1—endometrium—polycystic ovary syndrome	0.000668	0.0187	CbGeAlD
Doxepin—HRH2—endocrine gland—polycystic ovary syndrome	0.000666	0.0186	CbGeAlD
Doxepin—Bradycardia—Metformin—polycystic ovary syndrome	0.000665	0.0128	CcSEcCtD
Doxepin—Hepatitis—Metformin—polycystic ovary syndrome	0.000653	0.0126	CcSEcCtD
Doxepin—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00065	0.0125	CcSEcCtD
Doxepin—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000644	0.0124	CcSEcCtD
Doxepin—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000642	0.0124	CcSEcCtD
Doxepin—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000631	0.0177	CbGeAlD
Doxepin—Eye disorder—Metformin—polycystic ovary syndrome	0.000611	0.0118	CcSEcCtD
Doxepin—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000606	0.0117	CcSEcCtD
Doxepin—Flushing—Metformin—polycystic ovary syndrome	0.000606	0.0117	CcSEcCtD
Doxepin—Angiopathy—Metformin—polycystic ovary syndrome	0.000593	0.0114	CcSEcCtD
Doxepin—Immune system disorder—Metformin—polycystic ovary syndrome	0.00059	0.0114	CcSEcCtD
Doxepin—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000589	0.0114	CcSEcCtD
Doxepin—Chills—Metformin—polycystic ovary syndrome	0.000586	0.0113	CcSEcCtD
Doxepin—Erythema—Metformin—polycystic ovary syndrome	0.000569	0.011	CcSEcCtD
Doxepin—Malnutrition—Metformin—polycystic ovary syndrome	0.000569	0.011	CcSEcCtD
Doxepin—ADRA1D—endocrine gland—polycystic ovary syndrome	0.000568	0.0159	CbGeAlD
Doxepin—HTR2B—endometrium—polycystic ovary syndrome	0.000564	0.0158	CbGeAlD
Doxepin—Flatulence—Metformin—polycystic ovary syndrome	0.00056	0.0108	CcSEcCtD
Doxepin—Dysgeusia—Metformin—polycystic ovary syndrome	0.000557	0.0107	CcSEcCtD
Doxepin—Muscle spasms—Metformin—polycystic ovary syndrome	0.000547	0.0106	CcSEcCtD
Doxepin—Vision blurred—Metformin—polycystic ovary syndrome	0.000536	0.0103	CcSEcCtD
Doxepin—Tremor—Metformin—polycystic ovary syndrome	0.000533	0.0103	CcSEcCtD
Doxepin—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000528	0.0102	CcSEcCtD
Doxepin—HTR2B—uterus—polycystic ovary syndrome	0.000519	0.0145	CbGeAlD
Doxepin—Malaise—Metformin—polycystic ovary syndrome	0.000513	0.0099	CcSEcCtD
Doxepin—Syncope—Metformin—polycystic ovary syndrome	0.00051	0.00984	CcSEcCtD
Doxepin—HTR2B—adipose tissue—polycystic ovary syndrome	0.000508	0.0142	CbGeAlD
Doxepin—Palpitations—Metformin—polycystic ovary syndrome	0.000503	0.0097	CcSEcCtD
Doxepin—Loss of consciousness—Metformin—polycystic ovary syndrome	0.0005	0.00964	CcSEcCtD
Doxepin—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000497	0.0139	CbGeAlD
Doxepin—Hypertension—Metformin—polycystic ovary syndrome	0.000491	0.00947	CcSEcCtD
Doxepin—Myalgia—Metformin—polycystic ovary syndrome	0.000484	0.00934	CcSEcCtD
Doxepin—Chest pain—Metformin—polycystic ovary syndrome	0.000484	0.00934	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000481	0.00928	CcSEcCtD
Doxepin—Discomfort—Metformin—polycystic ovary syndrome	0.000478	0.00923	CcSEcCtD
Doxepin—ORM1—endocrine gland—polycystic ovary syndrome	0.000468	0.0131	CbGeAlD
Doxepin—Oedema—Metformin—polycystic ovary syndrome	0.000464	0.00896	CcSEcCtD
Doxepin—Infection—Metformin—polycystic ovary syndrome	0.000461	0.0089	CcSEcCtD
Doxepin—CHRM3—adipose tissue—polycystic ovary syndrome	0.000457	0.0128	CbGeAlD
Doxepin—Shock—Metformin—polycystic ovary syndrome	0.000457	0.00881	CcSEcCtD
Doxepin—HTR2B—adrenal gland—polycystic ovary syndrome	0.000456	0.0127	CbGeAlD
Doxepin—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000455	0.00878	CcSEcCtD
Doxepin—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000454	0.00877	CcSEcCtD
Doxepin—Skin disorder—Metformin—polycystic ovary syndrome	0.000451	0.0087	CcSEcCtD
Doxepin—KCNH2—endometrium—polycystic ovary syndrome	0.00045	0.0126	CbGeAlD
Doxepin—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000449	0.00866	CcSEcCtD
Doxepin—ADRA2C—endometrium—polycystic ovary syndrome	0.000444	0.0124	CbGeAlD
Doxepin—Anorexia—Metformin—polycystic ovary syndrome	0.000442	0.00854	CcSEcCtD
Doxepin—CHRM2—endocrine gland—polycystic ovary syndrome	0.000436	0.0122	CbGeAlD
Doxepin—Hypotension—Metformin—polycystic ovary syndrome	0.000434	0.00837	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000423	0.00816	CcSEcCtD
Doxepin—HTR2B—vagina—polycystic ovary syndrome	0.000422	0.0118	CbGeAlD
Doxepin—ADRA1A—adipose tissue—polycystic ovary syndrome	0.00042	0.0117	CbGeAlD
Doxepin—Paraesthesia—Metformin—polycystic ovary syndrome	0.000417	0.00804	CcSEcCtD
Doxepin—KCNH2—uterus—polycystic ovary syndrome	0.000414	0.0116	CbGeAlD
Doxepin—Dyspnoea—Metformin—polycystic ovary syndrome	0.000414	0.00798	CcSEcCtD
Doxepin—DRD2—pituitary gland—polycystic ovary syndrome	0.000413	0.0115	CbGeAlD
Doxepin—Somnolence—Metformin—polycystic ovary syndrome	0.000413	0.00796	CcSEcCtD
Doxepin—HTR2A—embryo—polycystic ovary syndrome	0.000411	0.0115	CbGeAlD
Doxepin—ADRA2C—uterus—polycystic ovary syndrome	0.000409	0.0114	CbGeAlD
Doxepin—Dyspepsia—Metformin—polycystic ovary syndrome	0.000409	0.00788	CcSEcCtD
Doxepin—HTR1A—adrenal gland—polycystic ovary syndrome	0.000408	0.0114	CbGeAlD
Doxepin—KCNH2—pituitary gland—polycystic ovary syndrome	0.000407	0.0114	CbGeAlD
Doxepin—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.000406	0.101	CrCbGaD
Doxepin—SLC6A2—adrenal gland—polycystic ovary syndrome	0.000405	0.0113	CbGeAlD
Doxepin—Decreased appetite—Metformin—polycystic ovary syndrome	0.000403	0.00779	CcSEcCtD
Doxepin—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000401	0.0112	CbGeAlD
Doxepin—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000401	0.00773	CcSEcCtD
Doxepin—Fatigue—Metformin—polycystic ovary syndrome	0.0004	0.00772	CcSEcCtD
Doxepin—ADRA2C—adipose tissue—polycystic ovary syndrome	0.0004	0.0112	CbGeAlD
Doxepin—SLC6A4—endocrine gland—polycystic ovary syndrome	0.000399	0.0112	CbGeAlD
Doxepin—CHRM1—endocrine gland—polycystic ovary syndrome	0.000397	0.0111	CbGeAlD
Doxepin—Constipation—Metformin—polycystic ovary syndrome	0.000397	0.00766	CcSEcCtD
Doxepin—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000382	0.00738	CcSEcCtD
Doxepin—CHRM3—female gonad—polycystic ovary syndrome	0.000382	0.0107	CbGeAlD
Doxepin—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00038	0.00732	CcSEcCtD
Doxepin—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000376	0.0105	CbGeAlD
Doxepin—Urticaria—Metformin—polycystic ovary syndrome	0.000369	0.00711	CcSEcCtD
Doxepin—Abdominal pain—Metformin—polycystic ovary syndrome	0.000367	0.00708	CcSEcCtD
Doxepin—KCNH2—adrenal gland—polycystic ovary syndrome	0.000364	0.0102	CbGeAlD
Doxepin—HRH1—endometrium—polycystic ovary syndrome	0.00036	0.0101	CbGeAlD
Doxepin—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000359	0.01	CbGeAlD
Doxepin—CHRM3—endocrine gland—polycystic ovary syndrome	0.000356	0.00994	CbGeAlD
Doxepin—HTR1A—endocrine gland—polycystic ovary syndrome	0.000354	0.0099	CbGeAlD
Doxepin—ADRA2A—endometrium—polycystic ovary syndrome	0.000354	0.0099	CbGeAlD
Doxepin—CYP2C19—vagina—polycystic ovary syndrome	0.000353	0.00987	CbGeAlD
Doxepin—SLC6A2—endocrine gland—polycystic ovary syndrome	0.000351	0.00982	CbGeAlD
Doxepin—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.000346	0.0863	CrCbGaD
Doxepin—KCNH2—female gonad—polycystic ovary syndrome	0.000339	0.00948	CbGeAlD
Doxepin—KCNH2—vagina—polycystic ovary syndrome	0.000337	0.00942	CbGeAlD
Doxepin—ADRA2C—female gonad—polycystic ovary syndrome	0.000334	0.00935	CbGeAlD
Doxepin—Asthenia—Metformin—polycystic ovary syndrome	0.000333	0.00643	CcSEcCtD
Doxepin—ADRA2C—vagina—polycystic ovary syndrome	0.000332	0.00929	CbGeAlD
Doxepin—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00033	0.00924	CbGeAlD
Doxepin—Pruritus—Metformin—polycystic ovary syndrome	0.000328	0.00634	CcSEcCtD
Doxepin—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000326	0.00913	CbGeAlD
Doxepin—ADRA2A—uterus—polycystic ovary syndrome	0.000326	0.00912	CbGeAlD
Doxepin—Trimipramine—ADRA1B—polycystic ovary syndrome	0.000326	0.0812	CrCbGaD
Doxepin—HRH1—adipose tissue—polycystic ovary syndrome	0.000325	0.00908	CbGeAlD
Doxepin—Promazine—ADRA1D—polycystic ovary syndrome	0.000324	0.0806	CrCbGaD
Doxepin—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00032	0.00896	CbGeAlD
Doxepin—DRD2—endocrine gland—polycystic ovary syndrome	0.00032	0.00895	CbGeAlD
Doxepin—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000319	0.00892	CbGeAlD
Doxepin—Diarrhoea—Metformin—polycystic ovary syndrome	0.000318	0.00613	CcSEcCtD
Doxepin—KCNH2—endocrine gland—polycystic ovary syndrome	0.000315	0.00881	CbGeAlD
Doxepin—Dizziness—Metformin—polycystic ovary syndrome	0.000307	0.00592	CcSEcCtD
Doxepin—Vomiting—Metformin—polycystic ovary syndrome	0.000295	0.00569	CcSEcCtD
Doxepin—Rash—Metformin—polycystic ovary syndrome	0.000293	0.00565	CcSEcCtD
Doxepin—Dermatitis—Metformin—polycystic ovary syndrome	0.000292	0.00564	CcSEcCtD
Doxepin—HRH1—adrenal gland—polycystic ovary syndrome	0.000291	0.00815	CbGeAlD
Doxepin—Headache—Metformin—polycystic ovary syndrome	0.000291	0.00561	CcSEcCtD
Doxepin—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000286	0.008	CbGeAlD
Doxepin—Imipramine—ADRA1D—polycystic ovary syndrome	0.000283	0.0706	CrCbGaD
Doxepin—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.000282	0.0702	CrCbGaD
Doxepin—Promazine—ADRA1B—polycystic ovary syndrome	0.000276	0.0688	CrCbGaD
Doxepin—Nausea—Metformin—polycystic ovary syndrome	0.000276	0.00532	CcSEcCtD
Doxepin—HTR2A—pituitary gland—polycystic ovary syndrome	0.000272	0.00762	CbGeAlD
Doxepin—HRH1—female gonad—polycystic ovary syndrome	0.000272	0.0076	CbGeAlD
Doxepin—HRH1—vagina—polycystic ovary syndrome	0.00027	0.00755	CbGeAlD
Doxepin—CYP1A2—endocrine gland—polycystic ovary syndrome	0.00027	0.00755	CbGeAlD
Doxepin—ABCB1—embryo—polycystic ovary syndrome	0.00027	0.00754	CbGeAlD
Doxepin—ADRA2A—female gonad—polycystic ovary syndrome	0.000267	0.00746	CbGeAlD
Doxepin—ADRA2A—vagina—polycystic ovary syndrome	0.000265	0.00742	CbGeAlD
Doxepin—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000256	0.00716	CbGeAlD
Doxepin—HRH1—endocrine gland—polycystic ovary syndrome	0.000253	0.00706	CbGeAlD
Doxepin—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000248	0.00694	CbGeAlD
Doxepin—HTR2A—adrenal gland—polycystic ovary syndrome	0.000243	0.0068	CbGeAlD
Doxepin—Imipramine—ADRA1B—polycystic ovary syndrome	0.000242	0.0602	CrCbGaD
Doxepin—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.00024	0.0599	CrCbGaD
Doxepin—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.000233	0.0581	CrCbGaD
Doxepin—HTR2A—vagina—polycystic ovary syndrome	0.000226	0.00631	CbGeAlD
Doxepin—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000221	0.00618	CbGeAlD
Doxepin—Trimipramine—ADRA1A—polycystic ovary syndrome	0.000219	0.0547	CrCbGaD
Doxepin—Promethazine—ADRA1A—polycystic ovary syndrome	0.000211	0.0527	CrCbGaD
Doxepin—HTR2A—endocrine gland—polycystic ovary syndrome	0.000211	0.0059	CbGeAlD
Doxepin—CYP2D6—female gonad—polycystic ovary syndrome	0.000207	0.00578	CbGeAlD
Doxepin—ABCB1—endometrium—polycystic ovary syndrome	0.000197	0.00552	CbGeAlD
Doxepin—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000195	0.00546	CbGeAlD
Doxepin—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000192	0.00538	CbGeAlD
Doxepin—Promazine—ADRA1A—polycystic ovary syndrome	0.000186	0.0463	CrCbGaD
Doxepin—ABCB1—uterus—polycystic ovary syndrome	0.000182	0.00508	CbGeAlD
Doxepin—ABCB1—pituitary gland—polycystic ovary syndrome	0.000179	0.00499	CbGeAlD
Doxepin—ABCB1—adipose tissue—polycystic ovary syndrome	0.000178	0.00497	CbGeAlD
Doxepin—Imipramine—ADRA1A—polycystic ovary syndrome	0.000163	0.0406	CrCbGaD
Doxepin—Amitriptyline—ADRA1A—polycystic ovary syndrome	0.000162	0.0403	CrCbGaD
Doxepin—ABCB1—adrenal gland—polycystic ovary syndrome	0.000159	0.00446	CbGeAlD
Doxepin—ABCB1—female gonad—polycystic ovary syndrome	0.000149	0.00416	CbGeAlD
Doxepin—ABCB1—vagina—polycystic ovary syndrome	0.000148	0.00413	CbGeAlD
Doxepin—ABCB1—endocrine gland—polycystic ovary syndrome	0.000138	0.00387	CbGeAlD
Doxepin—Desipramine—ADRB2—polycystic ovary syndrome	0.000114	0.0284	CrCbGaD
Doxepin—CHRM5—Signaling Pathways—IGF1—polycystic ovary syndrome	3.51e-06	2.12e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.51e-06	2.12e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	3.51e-06	2.11e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	3.51e-06	2.11e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—AKT2—polycystic ovary syndrome	3.51e-06	2.11e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.49e-06	2.1e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.48e-06	2.1e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	3.48e-06	2.1e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.48e-06	2.1e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.46e-06	2.09e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	3.46e-06	2.09e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.44e-06	2.07e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—INS—polycystic ovary syndrome	3.44e-06	2.07e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	3.44e-06	2.07e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	3.43e-06	2.07e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.43e-06	2.07e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	3.41e-06	2.06e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.39e-06	2.04e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.37e-06	2.03e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.37e-06	2.03e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.33e-06	2.01e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.33e-06	2.01e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.32e-06	2e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.32e-06	2e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	3.31e-06	2e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	3.31e-06	2e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	3.31e-06	2e-05	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.31e-06	1.99e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—TH—polycystic ovary syndrome	3.3e-06	1.99e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	3.3e-06	1.99e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	3.3e-06	1.99e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.26e-06	1.97e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	3.26e-06	1.97e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.24e-06	1.95e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	3.23e-06	1.95e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.22e-06	1.94e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	3.21e-06	1.94e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.13e-06	1.89e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.12e-06	1.88e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PPARG—polycystic ovary syndrome	3.1e-06	1.87e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.1e-06	1.87e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	3.1e-06	1.87e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.09e-06	1.86e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	3.08e-06	1.86e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.07e-06	1.85e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.07e-06	1.85e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—POMC—polycystic ovary syndrome	3.06e-06	1.85e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.06e-06	1.84e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.06e-06	1.84e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	3.06e-06	1.84e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.05e-06	1.84e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IRS2—polycystic ovary syndrome	3.05e-06	1.84e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—INS—polycystic ovary syndrome	3.05e-06	1.84e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	3.02e-06	1.82e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.02e-06	1.82e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.01e-06	1.81e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.01e-06	1.81e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3e-06	1.81e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	3e-06	1.81e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	2.99e-06	1.8e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.99e-06	1.8e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—LEP—polycystic ovary syndrome	2.98e-06	1.8e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.98e-06	1.8e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.98e-06	1.79e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.97e-06	1.79e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	2.97e-06	1.79e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	2.97e-06	1.79e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.96e-06	1.78e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	2.96e-06	1.78e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	2.96e-06	1.78e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.96e-06	1.78e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	2.95e-06	1.78e-05	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—IL6—polycystic ovary syndrome	2.95e-06	1.78e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	2.94e-06	1.77e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.89e-06	1.74e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.89e-06	1.74e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	2.88e-06	1.73e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.88e-06	1.73e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.87e-06	1.73e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.86e-06	1.72e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.86e-06	1.72e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.85e-06	1.72e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	2.85e-06	1.72e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.85e-06	1.72e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	2.83e-06	1.71e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.83e-06	1.71e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.82e-06	1.7e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.82e-06	1.7e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	2.81e-06	1.69e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.8e-06	1.69e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.79e-06	1.68e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—INS—polycystic ovary syndrome	2.79e-06	1.68e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.78e-06	1.68e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.78e-06	1.68e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.75e-06	1.66e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.75e-06	1.65e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.74e-06	1.65e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.74e-06	1.65e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.74e-06	1.65e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.74e-06	1.65e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.73e-06	1.65e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.73e-06	1.64e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	2.72e-06	1.64e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.72e-06	1.64e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.71e-06	1.63e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.71e-06	1.63e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	2.7e-06	1.63e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.68e-06	1.62e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.68e-06	1.62e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.68e-06	1.61e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.67e-06	1.61e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.67e-06	1.61e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.66e-06	1.6e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.64e-06	1.59e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.63e-06	1.59e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.63e-06	1.58e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	2.62e-06	1.58e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	2.61e-06	1.57e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.61e-06	1.57e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.6e-06	1.57e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.59e-06	1.56e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.58e-06	1.56e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.58e-06	1.56e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	2.58e-06	1.55e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.57e-06	1.55e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.57e-06	1.55e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	2.57e-06	1.55e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	2.56e-06	1.54e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—POMC—polycystic ovary syndrome	2.56e-06	1.54e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.56e-06	1.54e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	2.55e-06	1.54e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—INS—polycystic ovary syndrome	2.55e-06	1.54e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.54e-06	1.53e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.54e-06	1.53e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.53e-06	1.52e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.52e-06	1.52e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.52e-06	1.52e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.52e-06	1.52e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	2.52e-06	1.52e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.52e-06	1.52e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	2.51e-06	1.52e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	2.49e-06	1.5e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.48e-06	1.5e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.48e-06	1.5e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.48e-06	1.49e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.48e-06	1.49e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.47e-06	1.49e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.47e-06	1.49e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.46e-06	1.48e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.46e-06	1.48e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.46e-06	1.48e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.44e-06	1.47e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.44e-06	1.47e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.44e-06	1.47e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	2.43e-06	1.47e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.43e-06	1.47e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.43e-06	1.47e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.43e-06	1.46e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.4e-06	1.45e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.39e-06	1.44e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.36e-06	1.42e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.35e-06	1.42e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.35e-06	1.42e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.35e-06	1.41e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.34e-06	1.41e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.34e-06	1.41e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.32e-06	1.4e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.32e-06	1.4e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.31e-06	1.39e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.3e-06	1.39e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.29e-06	1.38e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.29e-06	1.38e-05	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—IL6—polycystic ovary syndrome	2.29e-06	1.38e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.28e-06	1.37e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	2.27e-06	1.37e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.26e-06	1.36e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.26e-06	1.36e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.2e-06	1.33e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.19e-06	1.32e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.19e-06	1.32e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.18e-06	1.31e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.16e-06	1.3e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.15e-06	1.29e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.13e-06	1.28e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.12e-06	1.28e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.09e-06	1.26e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	2.08e-06	1.25e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	2.02e-06	1.22e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.99e-06	1.2e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.99e-06	1.2e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.98e-06	1.19e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.97e-06	1.19e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.95e-06	1.17e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.94e-06	1.17e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.94e-06	1.17e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.93e-06	1.16e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.93e-06	1.16e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.9e-06	1.15e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.9e-06	1.14e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.89e-06	1.14e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.88e-06	1.14e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.88e-06	1.13e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.87e-06	1.13e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.87e-06	1.12e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.86e-06	1.12e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.86e-06	1.12e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	1.84e-06	1.11e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.83e-06	1.1e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.82e-06	1.1e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.82e-06	1.1e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	1.82e-06	1.09e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—INS—polycystic ovary syndrome	1.81e-06	1.09e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.79e-06	1.08e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.78e-06	1.07e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.75e-06	1.06e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.73e-06	1.04e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.69e-06	1.02e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL6—polycystic ovary syndrome	1.66e-06	9.98e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.65e-06	9.94e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.62e-06	9.78e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.62e-06	9.76e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.61e-06	9.73e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.61e-06	9.7e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.61e-06	9.68e-06	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.6e-06	9.66e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.59e-06	9.6e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.59e-06	9.58e-06	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL6—polycystic ovary syndrome	1.59e-06	9.56e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.57e-06	9.48e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.55e-06	9.35e-06	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.54e-06	9.3e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.5e-06	9.02e-06	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.49e-06	8.99e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	8.9e-06	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.35e-06	8.11e-06	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	7.83e-06	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.29e-06	7.79e-06	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.26e-06	7.58e-06	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.24e-06	7.46e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.21e-06	7.32e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.2e-06	7.22e-06	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.19e-06	7.18e-06	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.14e-06	6.88e-06	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	6.77e-06	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	6.75e-06	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	6.73e-06	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL6—polycystic ovary syndrome	1.11e-06	6.71e-06	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.1e-06	6.64e-06	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.1e-06	6.62e-06	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.02e-06	6.15e-06	CbGpPWpGaD
